Morningstar® Stock Report™

Carl Zeiss Meditec AG AFX

Último Precio
97.70
Cambio del día
0.05|0.05%

a 19/04/2024
17:38:30 CEST | EUR  Retraso mínimo: 15 minutos

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
97.25 - 97.7096.00 - 98.20137,446130,3888.73Bil
Último Cierre52 Week RangeP/UDividendo %ISIN
97.6572.60 - 126.0031.151.14DE0005313704

Cotización Carl Zeiss Meditec AG

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
Más...
Cuenta de Resultados
Ingresos1,646.791,902.842,089.30
Resultado Operativo373.61396.88348.12
Resultado Neto236.28293.91290.40
Beneficio Básico por Acción2.643.293.25
Num Medio Acciones diluidas en circulación898989
Balance
Activo Corriente1,604.021,791.851,911.73
Activos no corrientes791.951,030.961,121.20
Total Activo 2,395.972,822.823,032.92
Pasivo corriente448.12539.32561.65
Total Pasivo---
Capital Total1,659.332,015.102,159.45
Flujo de Caja
Flujo de caja operativo362.66188.20250.86
Inversiones de Capital-66.10-81.97-113.86
Flujo de Caja Libre296.56106.23137.00

En millones, excepto "EPS básico". La moneda es EUR.

Perfil de la compañía

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Sector

Atención sanitaria

Industria

Instrumentos y Suministros Médicos

Estilo de acciones

Media-Crecim

Fin Ejercicio Fiscal

septiembre

Empleados

4,823
Principales Características
Más...
Precio/Beneficio 12 m31.50
Precio/Valor contable4.04
Precio/Ventas TTM4.17
Crec Ingresos (media 3 a)16.09
Crec BPA (media 3 a)-
Margen operativo16.66
Margen neto13.90
ROE 12 m13.91
Deuda/Fondos propios0.06
Dividendos
AntÚltimo
Fecha declarada23/12/2215/12/23
Ex-Div23/03/2322/03/24
Pagado27/03/2326/03/24
Cantidad1.101.10